echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Langyu Group and Rhythm reached an exclusive license agreement for rare genetic obesity drugs

    Langyu Group and Rhythm reached an exclusive license agreement for rare genetic obesity drugs

    • Last Update: 2021-12-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 6, Langyu Group and Rhythm Pharmaceuticals, Inc.


    According to the terms of the agreement, Langyu will first seek regulatory approval and commercialization in China for certain indications, including: POMC biallelic defects, PCSK1 biallelic defects, LEPR biallelic defects, and Bardet-Biedl comprehensive Obesity and binge eating are rare diseases caused by symptoms or Alström syndrome


    According to the license agreement, Langyu Group will pay Rythmn an ​​advance payment in cash and stocks as well as milestone payments related to development and commercialization, and pay Rythmn a sales share based on the annual net sales in the Chinese market


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.